UPDATES AND NEWS

Latest Updates from Ness Therapeutics Inc.

Stay current on N001's development progress, regulatory milestones, and key announcements from Ness Therapeutics Inc.

Audience attending the Eureka Global Innovation Summit 2026 keynote in Basel, where Ness Therapeutics participated following Swiss Biotech Day.

Ness Therapeutics Inc. at the Eureka Global Innovation Summit 2026 in Basel and Lausanne

Ness Therapeutics Inc. participated in the Eureka Global Innovation Summit 2026 in Basel and Lausanne, advancing international conversations around N001.

Global Conference

min read

Ness Therapeutics Inc. at Swiss Biotech Day 2026 in Basel

Ness Therapeutics Inc. opened Swiss Biotech Day 2026 with strong international engagement across European government, defence, regulatory, and life sciences partnership conversations.

Deployable Respiratory Protection

min read

The Case for Deployable Respiratory Protection

A host-directed approach designed to be deployed quickly when respiratory threats emerge, before pathogen-specific tools are available.

Host Directed Approach

min read

Host-Directed vs. Pathogen-Specific: Understanding a Fundamental Distinction in Antiviral Development

Host-directed antiviral development focuses on activating the body’s innate defences at the site of exposure.

Respiratory Protection

min read

The Upper Airway as the Primary Point of Intervention in Respiratory Virus Protection

N001 is designed to provide early, host-directed respiratory virus protection at the upper airway, where infection first begins.

Program and Company Updates

Sign up to receive updates on N001's development milestones, regulatory progress, and key program announcements as Ness Therapeutics Inc. advances toward clinical readiness.

Thank you for your interest in Ness Therapeutics.

Something went wrong. Please try again.